Drug name - Uptravi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7205302 ACTELION Heterocyclic compound derivatives and medicines
Oct, 2026

(4 years from now)

US8791122 ACTELION Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
Aug, 2030

(7 years from now)

CN1516690A ACTELION Heterocyclic Derivative And Medicine
Apr, 2022

(5 months ago)

CN1301973C ACTELION Heterocyclic Derivative And Medicine
Apr, 2022

(5 months ago)

CN102459198A ACTELION Crystal
Jun, 2030

(7 years from now)

CN102459198B ACTELION Crystal
Jun, 2030

(7 years from now)

EP1400518A4 ACTELION Heterocyclic Compound Derivatives And Medicines
Apr, 2022

(5 months ago)

EP1400518B1 ACTELION Heterocyclic Compound Derivatives And Medicines
Apr, 2022

(5 months ago)

EP1400518A1 ACTELION Heterocyclic Compound Derivatives And Medicines
Apr, 2022

(5 months ago)

EP2447254A4 ACTELION Crystals
Jun, 2030

(7 years from now)

EP2447254A1 ACTELION Crystals
Jun, 2030

(7 years from now)

EP3275871A1 ACTELION Crystals
Jun, 2030

(7 years from now)

EP2447254B1 ACTELION Crystals
Jun, 2030

(7 years from now)

EP3275871B1 ACTELION Crystals
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173881 ACTELION Therapeutic compositions containing macitentan Aug, 2029

(6 years from now)

US9284280 ACTELION Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide Jun, 2030

(7 years from now)

US10828298 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide Dec, 2036

(14 years from now)

US10821108 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide Dec, 2036

(14 years from now)

Drugs and Companies using SELEXIPAG ingredient

Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag; Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1.8MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.